Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results
Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington et autres
us, Afrique du Sud, gb, il, tw, de, au, fr, it, br (code pays fourni par la source)
3 citations
Research and Practice in Thrombosis and Haemostasis